Novavax, Inc.NVAXNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank64
3Y CAGR-35.2%
5Y CAGR-14.7%
Year-over-Year Change
Research and development spending
3Y CAGR
-35.2%/yr
vs +63.3%/yr prior
5Y CAGR
-14.7%/yr
Recent deceleration
Acceleration
-98.4pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
4 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $336.82M | -13.9% |
| 2024 | $391.17M | -47.0% |
| 2023 | $737.50M | -40.3% |
| 2022 | $1.24B | -51.3% |
| 2021 | $2.53B | +239.3% |
| 2020 | $747.03M | +556.2% |
| 2019 | $113.84M | -34.5% |
| 2018 | $173.80M | +3.2% |
| 2017 | $168.44M | -29.2% |
| 2016 | $237.94M | - |